Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

May 20, 2024

Study Completion Date

December 31, 2024

Conditions

Increased Risk for Development of Breast Cancer

Interventions

DRUG

bazedoxifene plus conjugated estrogens

6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.

Trial Locations (1)

University of Kansas Medical Center, Kansas City

All Listed Sponsors

lead

Carol Fabian, MD

OTHER

NCT04821375 - Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers | Biotech Hunter | Biotech Hunter